Bionime Corporation operates within the Diagnostic substances sector. In addition to historical fundamental analyses, the complete report available to purchase compares Bionime with three other companies in this sector in Taiwan: Apex Biotechnology Corporation (2017 sales of 1.80 billion Taiwanese Dollars [US$58.38 million] of which 58% was Test Strip), Cowealth Medical Holding Co Ltd (3.04 billion Taiwanese Dollars [US$98.76 million] of which 96% was Depar. B(Sale Reagent&Other)), and OK Biotech Co Ltd (1.23 billion Taiwanese Dollars [US$40.10 million] ).

Sales Analysis. During the year ended December of 2017, sales at Bionime were 1.82 billion Taiwanese Dollars (US$59.20 million). This is an increase of 4.6% versus 2016, when the company's sales were 1.74 billion Taiwanese Dollars. This was the third consecutive year of growth at Bionime.